menu
    • menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Divestment","leadProduct":"Fursultiamine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":2.2999999999999998,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":2.2999999999999998,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Blackstone Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Blackstone Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Fursultiamine

    Menu

    Fursultiamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Takeda Pharmaceutical

                            Japan arrow
                            Luxepack
                            Not Confirmed

                            Takeda Pharmaceutical

                            Japan arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fursultiamine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $2,300.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion

                            Details : The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.

                            Brand Name : Alinamin

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 24, 2020

                            Lead Product(s) : Fursultiamine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $2,300.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth